NEWS
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed by a $15 million NIH and NIDA HEAL award. CEO Dr. Lynn Kirkpatrick highlighted the adaptability of Ensysce's TAAP technology in producing controlled-activation drug candidates. Human clinical studies are expected to begin within 12 to 18 months.
Positive
Selection of PF9001 as lead candidate in the OUD program.
PF9001 shows lower potential for cardiovascular side effects compared to traditional treatments.
Backed by a $15 million multi-year HEAL award from NIH and NIDA.
IND enabling studies for PF9001 to begin.
Human clinical studies expected within 12 to 18 months.
Negative
No immediate revenue from PF9001; clinical trials typically take years.
Potential risks and delays associated with clinical trials.
No mention of current revenue streams or profitability.
Positive
Selection of PF9001 as lead candidate in the OUD program.
PF9001 shows lower potential for cardiovascular side effects compared to traditional treatments.
Backed by a $15 million multi-year HEAL award from NIH and NIDA.
IND enabling studies for PF9001 to begin.
Human clinical studies expected within 12 to 18 months.
Negative
No immediate revenue from PF9001; clinical trials typically take years.
Potential risks and delays associated with clinical trials.
No mention of current revenue streams or profitability.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7416Visitors
Follow